BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

Priscilla Denise Zepeda-Lopez, Julio Cesar Salas-Alanis, Sonia Toussaint-Caire, Daniela Gutierrez-Mendoza, Elisa Vega-Memije, Saúl Lino Silva, Oscar Raul Fajardo-Ramírez, Gregorio Alcazar, María Guadalupe Moreno-Treviño, Hugo Alberto Barrera Saldaña

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: B-Raf is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. It has been shown that 50% of melanomas harbor activating BRAF mutations, with over 90% being the V600E mutation. Objective: The goal of this research was to determine the prevalence of the BRAF V600E mutation in patients from Central Mexico diagnosed with primary melanoma. Methods: Skin biopsies from 47 patients with melanoma were obtained from the dermatology department of the Hospital General 'Dr. Manuel Gea González' in Mexico City. For BRAF mutation determination, after DNA isolation, the gene region where the mutation occurs was amplified by PCR. Subsequently, the presence or absence of the V600E mutation was detected by Sanger sequencing performed at the private molecular diagnostic laboratory Vitagénesis in Monterrey, Mexico. Results: Of the 47 patients sampled, 6.4% harbored the V600E mutation. No statistical significance was found between mutations and the type of tumor.

Original languageEnglish
Pages (from-to)241-245
Number of pages5
JournalCase Reports in Oncology
Volume9
Issue number1
DOIs
Publication statusPublished - 20 May 2016

Fingerprint

Melanoma
Mutation
Mexico
MAP Kinase Signaling System
Geum
Molecular Pathology
Protein-Serine-Threonine Kinases
Hospital Departments
Mitogen-Activated Protein Kinase Kinases
Dermatology
General Hospitals
Protein Kinases
Biopsy
Polymerase Chain Reaction
Skin
DNA
Research
Genes
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Zepeda-Lopez, P. D., Salas-Alanis, J. C., Toussaint-Caire, S., Gutierrez-Mendoza, D., Vega-Memije, E., Lino Silva, S., ... Barrera Saldaña, H. A. (2016). BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma. Case Reports in Oncology, 9(1), 241-245. https://doi.org/10.1159/000445939
Zepeda-Lopez, Priscilla Denise ; Salas-Alanis, Julio Cesar ; Toussaint-Caire, Sonia ; Gutierrez-Mendoza, Daniela ; Vega-Memije, Elisa ; Lino Silva, Saúl ; Fajardo-Ramírez, Oscar Raul ; Alcazar, Gregorio ; Moreno-Treviño, María Guadalupe ; Barrera Saldaña, Hugo Alberto. / BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma. In: Case Reports in Oncology. 2016 ; Vol. 9, No. 1. pp. 241-245.
@article{c12ee3790cda40e3bc476d016b6086ef,
title = "BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma",
abstract = "Background: B-Raf is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. It has been shown that 50{\%} of melanomas harbor activating BRAF mutations, with over 90{\%} being the V600E mutation. Objective: The goal of this research was to determine the prevalence of the BRAF V600E mutation in patients from Central Mexico diagnosed with primary melanoma. Methods: Skin biopsies from 47 patients with melanoma were obtained from the dermatology department of the Hospital General 'Dr. Manuel Gea Gonz{\'a}lez' in Mexico City. For BRAF mutation determination, after DNA isolation, the gene region where the mutation occurs was amplified by PCR. Subsequently, the presence or absence of the V600E mutation was detected by Sanger sequencing performed at the private molecular diagnostic laboratory Vitag{\'e}nesis in Monterrey, Mexico. Results: Of the 47 patients sampled, 6.4{\%} harbored the V600E mutation. No statistical significance was found between mutations and the type of tumor.",
author = "Zepeda-Lopez, {Priscilla Denise} and Salas-Alanis, {Julio Cesar} and Sonia Toussaint-Caire and Daniela Gutierrez-Mendoza and Elisa Vega-Memije and {Lino Silva}, Sa{\~A}ºl and Fajardo-Ram{\~A}­rez, {Oscar Raul} and Gregorio Alcazar and Moreno-Trevi{\~A}±o, {Mar{\~A}­a Guadalupe} and {Barrera Salda{\~A}±a}, {Hugo Alberto}",
year = "2016",
month = "5",
day = "20",
doi = "10.1159/000445939",
language = "English",
volume = "9",
pages = "241--245",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "1",

}

Zepeda-Lopez, PD, Salas-Alanis, JC, Toussaint-Caire, S, Gutierrez-Mendoza, D, Vega-Memije, E, Lino Silva, S, Fajardo-Ramírez, OR, Alcazar, G, Moreno-Treviño, MG & Barrera Saldaña, HA 2016, 'BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma', Case Reports in Oncology, vol. 9, no. 1, pp. 241-245. https://doi.org/10.1159/000445939

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma. / Zepeda-Lopez, Priscilla Denise; Salas-Alanis, Julio Cesar; Toussaint-Caire, Sonia; Gutierrez-Mendoza, Daniela; Vega-Memije, Elisa; Lino Silva, Saúl; Fajardo-Ramírez, Oscar Raul; Alcazar, Gregorio; Moreno-Treviño, María Guadalupe; Barrera Saldaña, Hugo Alberto.

In: Case Reports in Oncology, Vol. 9, No. 1, 20.05.2016, p. 241-245.

Research output: Contribution to journalArticle

TY - JOUR

T1 - BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

AU - Zepeda-Lopez, Priscilla Denise

AU - Salas-Alanis, Julio Cesar

AU - Toussaint-Caire, Sonia

AU - Gutierrez-Mendoza, Daniela

AU - Vega-Memije, Elisa

AU - Lino Silva, Saúl

AU - Fajardo-Ramírez, Oscar Raul

AU - Alcazar, Gregorio

AU - Moreno-Treviño, María Guadalupe

AU - Barrera Saldaña, Hugo Alberto

PY - 2016/5/20

Y1 - 2016/5/20

N2 - Background: B-Raf is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. It has been shown that 50% of melanomas harbor activating BRAF mutations, with over 90% being the V600E mutation. Objective: The goal of this research was to determine the prevalence of the BRAF V600E mutation in patients from Central Mexico diagnosed with primary melanoma. Methods: Skin biopsies from 47 patients with melanoma were obtained from the dermatology department of the Hospital General 'Dr. Manuel Gea González' in Mexico City. For BRAF mutation determination, after DNA isolation, the gene region where the mutation occurs was amplified by PCR. Subsequently, the presence or absence of the V600E mutation was detected by Sanger sequencing performed at the private molecular diagnostic laboratory Vitagénesis in Monterrey, Mexico. Results: Of the 47 patients sampled, 6.4% harbored the V600E mutation. No statistical significance was found between mutations and the type of tumor.

AB - Background: B-Raf is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. It has been shown that 50% of melanomas harbor activating BRAF mutations, with over 90% being the V600E mutation. Objective: The goal of this research was to determine the prevalence of the BRAF V600E mutation in patients from Central Mexico diagnosed with primary melanoma. Methods: Skin biopsies from 47 patients with melanoma were obtained from the dermatology department of the Hospital General 'Dr. Manuel Gea González' in Mexico City. For BRAF mutation determination, after DNA isolation, the gene region where the mutation occurs was amplified by PCR. Subsequently, the presence or absence of the V600E mutation was detected by Sanger sequencing performed at the private molecular diagnostic laboratory Vitagénesis in Monterrey, Mexico. Results: Of the 47 patients sampled, 6.4% harbored the V600E mutation. No statistical significance was found between mutations and the type of tumor.

UR - http://www.scopus.com/inward/record.url?scp=84964258813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964258813&partnerID=8YFLogxK

U2 - 10.1159/000445939

DO - 10.1159/000445939

M3 - Article

C2 - 27194985

VL - 9

SP - 241

EP - 245

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 1

ER -

Zepeda-Lopez PD, Salas-Alanis JC, Toussaint-Caire S, Gutierrez-Mendoza D, Vega-Memije E, Lino Silva S et al. BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma. Case Reports in Oncology. 2016 May 20;9(1):241-245. https://doi.org/10.1159/000445939